Calithera Biosciences, Inc. (CALA)
OTCMKTS · Delayed Price · Currency is USD
0.0010
+0.0008 (400.00%)
Nov 3, 2025, 11:42 AM EST
Calithera Biosciences Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
974.00
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 9.75M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 22.25M | -3.70M | -14.26% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Federal National Mortgage Association | 28.47B |
| Federal Home Loan Mortgage | 22.51B |
| First National of Nebraska | 1.89B |
| Central Bancompany | 914.42M |
| W.T.B. Financial | 403.16M |
| Farmers & Merchants Bank of Long Beach | 270.70M |
| First National Bank Alaska | 204.38M |
| Wilson Bank Holding Company | 197.85M |
Calithera Biosciences News
- 2 years ago - Calithera Biosciences Announces Update on Complete Liquidation and Dissolution - GlobeNewsWire
- 3 years ago - Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution - GlobeNewsWire
- 3 years ago - Calithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call Transcript - Seeking Alpha
- 3 years ago - Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update - GlobeNewsWire
- 3 years ago - Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 - GlobeNewsWire
- 3 years ago - Calithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidate - Market Watch
- 3 years ago - Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer - GlobeNewsWire
- 3 years ago - Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference - GlobeNewsWire